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A Remedy for Blame – Accountability
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The sultry summer day on campus
belied the atmosphere inside as
the proceedings of an expert panel
meeting, titled Creating a Framework
for Accountable Care, unfolded. The
conveners – Jefferson’s School of
Population Health and the team from
Eli Lilly and Company – and panelists
were enthusiastic about the Affordable
Care Act’s (ACA) emphasis on
accountability and expressed optimism
about the sea change already under way
in US health care delivery.

By Michael Kobernick, MD, MS............. 10

Fast forward to early November,
several weeks after the rocky launch
of Healthcare.gov. True, the electronic
enrollment technology fell woefully
short. True, some of us will not be able
to continue buying insurance plans that
fail to provide coverage that meets the
ACA’s minimum standards. But, as
with any large, complex initiative, fits
and starts are to be expected – the real
danger lies in focusing too narrowly on
the glitches.
This newsletter was jointly developed and
subject to editorial review by Jefferson
School of Population Health and Lilly
USA, LLC, and is supported through
funding by Lilly USA, LLC. The content
and viewpoints expressed are those of the
individual authors, and are not necessarily
those of Lilly USA, LLC or the Jefferson
School of Population Health.

To my mind, this first installment of our
new Prescriptions for Excellence in Health
Care series could not come at a more
opportune time because it takes a broad

view of another important aspect of the
law (ie, accountable care), celebrates
some early successes, and explores new
approaches to future challenges.
The first article, “Accountable Care
2013: Are We There Yet?,” describes the
journey to “there” by exploring manifold
paths to potential failure or imminent
success. In “Creating a Framework for
Accountable Care: Ensuring Product
Value,” we delve into an often ignored
aspect of accountability – the need for
manufacturers of health care devices and
pharmaceuticals to demonstrate clinical
and economic effectiveness relative to
comparable alternatives.
My personal favorite title is “Moneyball
for Health Care.” The premise of the
article is that US health care should
follow American baseball’s example
Prescriptions for Excellence in Health
Care is brought to Population Health
Matters readers by Jefferson School
of Population Health in partnership
with Lilly USA, LLC to provide
essential information from the quality
improvement and patient safety arenas.

(continued on page 2)
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and begin to look at data in different,
smarter ways that will impact the
bottom line. Last but not least,
“Redefining Care Management to
Address Increasing Fragmentation in
Health Care” is a compelling reminder

that integration is an essential
ingredient in accountable care.

more accountability into our systems.
Accountability leaves no room for blame.

The “blame games” now playing out
at all levels of government and in the
media make a clear case for building

As always, I welcome feedback from
our readers at david.nash@jefferson.edu.

A Message from Lilly
Ensuring Access to New Technology in Accountable Care Organizations
By Derek L. Asay

This issue of Prescriptions for
Excellence in Health Care focuses on
a number of important aspects of
Accountable Care Organizations
(ACOs) and what it will take to
make them successful in the United
States. Without question, we have
opportunities to improve the quality
of our health care system while better
managing costs. Accountable care in
the United States shows promise, but
we must be mindful to implement
those incentives that will lead to the
outcomes and costs that we all want.

increase in negative incentives
such as incentives to stint on care
or undersupply services, [and]
shift costs,” among other things.2
ACO metrics, particularly within
the MSSP, may create misaligned
incentives relative to innovative
technologies. Specifically, new
technology costs likely are not
included in the benchmark cost
and any potential savings associated
with the new technology may not
be realized within the relevant time
window of measurement.

At the end of 2013, more than
360 Medicare ACOs had been
established, serving more than 5.3
million Medicare beneficiaries.1
Although it has been less than 4
years since the ACA was signed into
law, almost 10% of the Medicare
population now receives health care
from an ACO.

Ensuring access to innovative
new technologies is critical to the
long-term success of our health
care system. It follows that ACO
metrics should not disincentivize the
appropriate use of new technologies.
The range of options available to
ensure beneficiary access to new
technologies includes:

As noted in the Centers for
Medicare & Medicaid Services’
(CMS) Medicare Shared Savings
Program (MSSP) Proposed Rule
(2011), in risk-based arrangements
wherein “providers of services
and suppliers have an increased
motivation to control spending
and achieve efficiencies, it would
be reasonable to anticipate an

•C
 reating reimbursement carveouts for new technologies.
•M
 onitoring ACO adoption of
new technologies.
•E
 ncouraging ACOs to address
new technologies in their clinical
guidelines.

• Fostering adherence to
compendia guidelines to ensure
appropriate beneficiary access to
new technologies.
Carve-Outs
One way to ensure that patients
continue to have access to innovative
medical technologies is to carve
them out of both the benchmark
and performance year expenditures
for ACOs. When the decision
to use such therapies is removed
from the calculation of the ACO’s
expenditures for purposes of
determining shared savings, there
is no incentive to lower costs by
denying patients access to them.
Quality Assessment
The development and implementation
of quality measures to assess an
entity’s adoption of new technologies
is another approach to ensuring
appropriate beneficiary access to
innovative technologies. Monitoring
adherence to new technology quality
measures as well as ACO access levels
for new technologies will help reduce
inappropriate restrictions on medical
innovation.
Practice Guidelines
Development of evidence-based
medical practices is important
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for any ACO, regardless of its
participation in the MSSP. CMS’
MSSP final rule requires Medicare
ACOs to develop evidence-based
medical practices or clinical
guidelines for delivering coordinated
care, especially for diagnoses
with potential for significant
quality improvements and cost
savings.3 Beneficiary access to new
technologies should be addressed in
these guidelines and processes.
Compendia Guidelines
ACOs’ evidence-based clinical
guidelines should adhere to
recognized compendia guidelines
for the use of drugs and biologics.
A drug compendia guideline lists
appropriate uses of drugs and
biologics as defined in clinical
practice guidelines based on
the evaluation of evidence from
scientific literature, integrated with
expert judgment in a consensusdriven process.

The incentive to reduce costs
that is inherent in any risk-based
arrangement may lead to negative
consequences with regard to
decisions about the care beneficiaries
receive and their access to specific
procedures and new technologies.
Therefore, steps must be taken
to ensure that ACO-generated
“savings” reflect real quality and
efficiency gains. Most importantly,
we must ensure that the best interest
of the patient is at the forefront
when all clinical decisions, including
treatment recommendations and
prescribing decisions, are made.
Paramount to the integrity of any
ACO program is monitoring how
savings are generated (eg, identifying
and understanding any changes in
coding patterns). Details regarding
savings generated and other pertinent
information concerning an ACO’s
operation and performance should be
made publicly available. Transparency
will help ensure against inappropriate

3

cost-saving practices (eg, costshifting), facilitate the sharing of best
practices, and hold ACOs accountable
for producing savings through qualitydriven changes.
ACOs are viewed as leaders in
health care reform for their use of
innovative service delivery models.
They also should be seen as leaders
in evaluating and adopting innovative
medical technologies. By doing so,
they will keep patients at the center of
everything that is done in health care.
Derek L. Asay is Senior Director,
Government Strategy, Federal Accounts
and Quality for Lilly USA, LLC, the
U.S. affiliate of Eli Lilly and Company.
References
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Accountable Care 2013: Are We There Yet?
By Robert I. Field, JD, MPH, PhD
Accountable care is an idea whose time
has come. Or is it? Initiatives are under
way on several fronts to build health
care systems that are accountable for
their outcomes and costs, but we have
been here before. Will accountable
care finally transform American health
care, or are today’s efforts just another
chapter in a long-running saga?
The Vision of Accountable Care
At its core, the call for accountable
care is a response to 2 fundamental

and interrelated shortcomings in the
American health care system. One is
the relentless rise in costs. The other is
a pervasive inconsistency in quality.

than anywhere else. Health care now
consumes more than 17% of the
American economy.2 It is expected to
exceed 20% within the next few years.3

In terms of costs, the United States
has the most expensive health care
system in the world. We spend at least
50% more per capita on health care
than any other developed country,
and almost twice as much as several
of them.1 Moreover, our rate of
spending growth is accelerating faster

Despite this level of spending, our
health outcomes are no better and, in
some regards, are worse than those
in much of the developed world. The
United States trails several other
developed countries on numerous
(continued on page 4)
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measures including life expectancy,
infant mortality, and mortality
attributable to health care.4 Clearly, we
are doing something wrong.
In terms of quality, the American health
care system is plagued by errors that
injure and kill thousands of patients
every year, causing as many as 100,000
deaths annually by one estimate.5
Medical practice varies widely across
regions of the country and even within
regions, producing dramatic disparities
in costs without discernible differences
in outcomes.6 The obvious conclusion
is that good medicine is practiced
inconsistently at best.
The vision of accountable care is to
address these problems by restructuring
relationships among providers,7 thereby
eliminating incentives that promote
inefficient and ineffective care and
replacing them with rewards that
encourage accountability for the costs
incurred and outcomes produced.
This, it is hoped, will rid the system of
clinical behavior that inflates costs and
ignores evidence of effectiveness.
Accountable Care Initiatives of the Past
The movement for accountable care
first took root on a wide scale in the
1990s with the creation of what were
known as “integrated delivery systems”
or IDSs. These collections of different
providers within a single organizational
structure typically included hospitals,
physicians, and providers of ancillary
services. They tried to align incentives
and oversee care to promote efficiency
and effectiveness.8
Versions of IDSs had existed for
decades, with some led by hospitals (eg,
the Mayo Clinic, the Cleveland Clinic,
Geisinger Health System) and others
by insurance companies (eg, KaiserPermanente). The new iterations of
the 1990s tried to integrate care with

more dispersed provider networks.
Although some of these systems made
major strides in coordinating care, the
vision of true provider accountability
remained largely unfulfilled. Too often,
incentives were inconsistently and
inappropriately aligned, and many
constituent providers continued to
be compensated based on the volume,
rather than the quality, of services
they rendered.9
Reasons Why Accountable Care May
Succeed This Time
The movement for accountable care
has reemerged in the last few years
with renewed vigor. Will it turn out
differently this time? There are several
reasons to think that it will.
First and foremost, information
technology has advanced tremendously
since the 1990s and is now
more capable of supporting care
coordination and oversight. Medical
record systems are more advanced and
new technological capabilities, such as
home monitoring of clinical indicators,
have emerged.10 The Internet, which
was just developing as a commercial
tool in the 1990s, has greatly
expanded the horizons of electronic
communication.
Coupled with these advances is an
increased willingness of physicians and
other clinicians to use technology. The
relative comfort with electronic records
and other technological applications
can be attributed to more hands-on
experience among providers in general
and greater technological savvy among
a new generation of physicians.
New physicians also are more
accustomed to alternative
compensation plans that reward
outcomes rather than volume of
services. Their expectations are less
likely to be linked to the old way of

doing things. At the same time, a
growing number of large payers have
taken active roles in crafting innovative
reimbursement plans.11
Finally, today’s movement for
accountable care is supported by major
new government initiatives. The
Health Information Technology for
Economic and Clinical Health Act
(2009) offers physicians significant
financial incentives for adopting
electronic records and using them in a
meaningful way.12 The Affordable Care
Act (2010) promotes the formation
of accountable care organizations –
alliances of hospitals, physicians, and
other providers that build on the
IDS concept of the 1990s to enhance
quality and control costs.13
Reasons Why Accountable Care May
Still Fall Short
Although these developments are cause
for optimism, clouds still linger on
accountable care’s horizon. A major
threat is the lack of sufficient primary
care capacity.14 Through their role in
overseeing all aspects of care, primary
care providers serve as linchpins for
care coordination in many accountable
care systems.15 However, the number of
American physicians entering primary
care remains low and shows no signs of
increasing. Allied health professionals
(eg, nurse practitioners, physician
assistants), who could fill some of the
need, require years of training.
Accountable care also faces some of the
same social and professional resistance
that has stymied it in the past. The
American health care system is huge
and, like most massive enterprises,
resistant to change. Many physicians
continue to cherish their autonomy
and resent the oversight that care
coordination can impose. Although a
new generation of physicians may be
more accepting of alternative practice
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paradigms, they do not yet dominate
the profession.
Finally, fee-for-service reimbursement
remains the norm for much of
American health care.16 Innovations
abound, but many large payers,
including Medicare, continue to
pay physicians largely based on the
number, rather than the quality, of
services they render. It is difficult for
a provider system to restructure its
incentives when the external funding
environment remains mired in the past.
The Bottom Line: Cause for
Cautious Optimism
What should we expect from the latest
movement for accountable care? Has
its time finally arrived? Although
challenges remain, the balance of
positive factors suggest that it has.
Information technology has grown
in sophistication and now offers
many of the capabilities necessary for
coordinating care systems. Providers
are more accepting of accountability
and the limits on clinical autonomy
that it can impose. Many major
payers, including insurance companies,
large employers, and Medicare, are

testing innovative approaches to
reimbursement. And government
policy is more actively supporting and
encouraging accountable care than it
has at any time in the past.
The dream of accountable care is
getting closer to reality every day.
It may take longer to reach fruition
than many had hoped, but its
widespread implementation is within
reach. Even the most obstinate of
systems can eventually change its
antiquated ways, and American health
care is no different.
Robert I. Field, JD, MPH, PhD, is
Professor of Law and Professor of Health
Management and Policy at Drexel
University. He can be reached at:
robert.field@drexel.edu.
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Creating a Framework for Accountable Care: Ensuring Product Value
By Rita E. Numerof, PhD
The US health care system is currently
undergoing what ultimately will be
a radical transformation driven by
unsustainable cost increases, increasing
regulation, and shifting power
relationships among payers, providers,
physicians, and patients. Technology
advances are accelerating the pace
of innovation, while rising costs and
demands for affordable health care and

greater transparency are challenging
the economics and traditional business
assumptions of the industry.
At the same time, health policy shifts
brought about by the Patient Protection
and Affordable Care Act are placing
increased accountability and cost
pressures on providers to improve patient
safety, quality of care, and consistency

of care delivered. In response, payers
(government and private) are actively
engaged in changing the way physicians
and hospitals are paid. These changes
include greater emphasis by payers and
other stakeholders on requiring value
for payment (eg, pay for performance,
bundled payment initiatives).
(continued on page 6)
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In the broader context of constrained
resources, all those who pay for care –
including providers, payers, and
consumers/patients – have become more
focused on the “value” they receive.
In addition, an increasingly educated
and information-driven generation
is demanding – and receiving – more
data about the quality and outcomes
associated with specific institutions,
procedures, and individual doctors.
Providers, payers, and consumers
alike are escalating their demands for
improved economic and clinical value.
In addition, the trend of health care
provider consolidation and physician
employment has gained momentum over
the past several years. Integrated systems
and Accountable Care Organizations
likely will further reduce suppliers’
access to physicians as they join larger
group practices or become employed by
hospital-based organizations.
Collectively, these pressures are causing
providers to impose more structure
on care delivery in an effort to reduce
cost and improve quality – in effect,
improving their organizations’ ability to
provide “accountable care.” As a practical
matter, hospital leaders must focus on
understanding the actual cost of care and
how their organizations will charge and
be paid for services. As new payment
systems are implemented, there is more
emphasis on links between payment
and quality; for example, Medicare’s
refusal to reimburse hospitals for
services associated with “never events.”
As payment is increasingly linked to
quality, administrative and clinical
leaders must find new ways to reduce
unnecessary variation in medical practice
and streamline operations, including the
supply chain, both to improve care and
manage costs more effectively.
The push for accountability in
delivering higher quality care at lower

costs has significant implications
for manufacturers; for instance, the
diminished role of individual physicians
in decision making about products.
Going forward, committees will make
decisions about which products to use.
There will be fewer but larger provider
customers, requiring more sophisticated
sales capabilities on the part of
manufacturers. With greater transparency
and more links between payment and
outcomes, there also will be increased
pricing pressure on product companies.

the condition addressed, save costs, and
improve outcomes.

Product selection will not simply
be focused on price; rather it will be
on selecting products with clearly
demonstrated benefits over competitor
products. Manufacturers should
anticipate that providers will engage in
aggressive formulary management and
give preference to those products that
demonstrate value in terms of safety,
efficacy, and cost. In short, manufacturers
must be able to demonstrate the economic
and clinical value of their products
compared to alternatives.

Such an approach requires the
integration of a broader relevant
stakeholder perspective on value wherein
every market need and product benefit
is evaluated through the lens of “What
is it worth?” This is especially true when
comparing a new product to generics
and other products that already exist in
the marketplace. Strengthening a value
proposition to providers – and payers –
requires data that demonstrate reduced
costs and/or improved clinical outcomes
compared to alternatives. Successful
manufacturers must demonstrate the
value of their products in efforts to
achieve accountable care.

To demonstrate a product’s clinical
value, manufacturers must have the
ability to provide data on the value of
a new product in terms of its potential
to improve patient outcomes, patient
management, and overall treatment
costs. This perspective requires a
broader view of a product in the context
of clinical use, and its potential impact
on economic and clinical outcomes.
Fully identifying the potential value of
products requires looking beyond product
attributes such as physician ease of use
or a specific product attribute. Focusing
narrowly on individual physicians’
interests often leads to head-to-head
comparisons with similar products and,
at times, overemphasis on single attribute
superiority. Instead, new products should
be evaluated on how they potentially
improve current treatment regimens for

Example: For comparative purposes,
determining the potential of a new drug as
a substitute for multiple drugs in a current
therapeutic regimen could be of great
value. Demonstrating equivalent efficacy
(vs. superiority) may be sufficient if the
product has an improved dosing frequency
and improved patient adherence, or a
reduction in the number of medications or
physician visits required for treatment.

As manufacturers become more
sophisticated in presenting economic
and clinical value data to providers,
hospitals will need to adopt processes
for evaluating new products. Because
the health care delivery team will be
tasked with managing the internal
decision-making process regarding
product decisions, they must understand
what value a new product will add to
an existing treatment regimen and
effectively evaluate the evidence on
products. Having such processes in
place may create new opportunities for
hospitals to partner with manufacturers.
Rita E. Numerof, PhD, is President of
Numerof & Associates, Inc. She can be
reached at: rnumerof@nai-consulting.com.
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Moneyball for Health Care
By Brian Silverstein, MD
Everyone agrees that US health care is
expensive and that there must be a better
way. However, there is considerable
uncertainty regarding the actual root
cause of the problems and no clear
solutions. Perhaps there is an opportunity
to use data differently to implement
strategies that can move the system
forward one piece at a time.

used to predict wins in baseball has
fundamentally transformed how teams
value players. The innovative concept
known as “moneyball” uses the data
and information differently to assemble
winning baseball teams for less money.
When applied to health care, the concept
would lead to our using data differently to
take better care of patients for less money.

By any measure, we spend more on health
care than any other country, and yet the
outcomes we achieve are disappointing.
Confounding variables, including
our unhealthy lifestyles, social and
environmental factors, and malpractice
issues, cloud the degree to which the
health care system itself is producing
suboptimal health outcomes. At the same
time, we hear anecdotes about the world’s
elite flying to the United States because
of our superior outcomes for acute care.
How can we make sense of this?

Today, much that we do in acute care is
based on flawed assumptions, similar to
the way in which baseball players were
valued. “Moneyball” for health care
takes a different approach, using data
and novel care models to ensure that
patients get what they need when they
need it (or even before they know they
need it) (Figure 1), and resulting in
better outcomes for a lower total cost.

Reconciling these paradoxical statements
is confusing; however, a resolution may
be found by using a different frame of
reference. We have the best acute care
system in the world but we fall woefully
short at managing chronic disease and
delivering preventive care. Because
ours is chiefly an acute care system, our
models fail to address the behavioral,
social, and economic determinants that
affect our health and result in additional
cost. Our focus on services and
procedures rather than the total patient
has made us proficient at delivering high
volume irrespective of total value.
An unlikely source may provide some
insights for a path forward. I believe
that baseball has something to teach us
about using data to improve value. A
recent evolution in the data elements

The key is delivering the right health
care in the right amount at the right

time. Today’s system is designed to
deliver an abundance of acute care
with insufficient attention to care
coordination. For example, there is clear
evidence that patients receive too many
cardiac interventions that range from
the rare criminal case (ie, stents placed
in normal cardiac vessels) to the more
common examples of stents placed in
patients when the evidence suggests
that medical management and lifestyle
modification will result in similar
outcomes.1 Although less acute care can
produce better total outcomes, it is very
challenging in our current environment
to implement these changes.
A Framework for “Moneyball”:
Population Health
To break out of the current mode, the
starting point is having a population to
manage. This is more important than
building infrastructure and capabilities.

Figure
forfor
Health
Care
Figure1.1.Moneyball
Moneyball
Health
Care

Identify Population and Create Registry
Risk Contract (Medicare Advantage, Commercial,
Medicaid, Employer)

Fee For Service with Attribution (Medicare,
Commercial)

Perform Analytics
HRA

Claims Data

Clinical Data

Lab Results

Pharmacy

Create Segments
Preventive Screenings

At Risk

Chronic Disease Gaps in
Care

High Cost

Target Interventions
Case
Management

Care
Management

Social
Workers

Medication
Reconciliation

Transitions In
Care

Referral
Management

Remote
Monitoring

Measurement and Monitoring
Quality
HRA,
health
riskrisk
assessment
HRA,
health
assessment

Cost

(continued on page 8)
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There must be a financial opportunity
to improve care for this population
and data must be available to make
this possible. Self-insured employers
already are well situated in this regard,
and providers are seeking ways to
acquire a population through riskbased contracts and, more commonly,
attribution in a fee-for-service contract.
Once there is accountability for a
population, the next step is to analyze
and segment the population with an
eye toward improving value. Some
examples include identification of:
(1) Gaps in care wherein patients’
needs for screening and their
existing conditions can be
improved (eg, vaccines, screening
tests, checking HbA1C in all
patients with diabetes).
(2) Opportunities to improve outcomes
through better care management
(eg, implementing programs to
avoid unnecessary emergency
department visits and hospital
admissions, assessing the value
proposition for specific providers
for a given clinical condition).
Each of these interventions must be
evaluated carefully to ensure that:
• The segment has been correctly
defined.
• An opportunity exists for
implementing the intervention in
the defined population segment.
• There is sufficient time to achieve
positive results.
Typically, it takes 5 to 10+ years to
see a positive impact from screening
programs whereas initiatives that target
transitions of care often yield results in
a few months.

Figure 2. Population Health – A Different Business
Fee-for-Service Business

Population Health

Customer

People who are admitted (or
use outpatient services)

Everyone who pays for coverage or is
enrolled in a plan/program

Revenue

Paid per unit of service

Monthly fixed amount

Expenses

Primarily labor and facilities

Health care services

Data Systems

Cost accounting and billing

Predictive models and care
management

Key to Success

Keep occupancy high and
expenses low

Increase management and monitoring
to reduce unnecessary care

Value-Driven Solutions and Interventions
The earliest adopters of health care
“moneyball” are employers. They
focus on prevention and wellness and
typically manage a population for a
sufficient period of time to benefit
from the investment. Because insurers
and providers have been unable to
manage cost increases, employers
are shifting their focus to near-term
opportunities that may make a large
financial impact. For instance:
•C
 reating care coordination benefits
(eg, Boeing provided resources
and created financial incentives
for providers to deliver high-value
health care).
•M
 odifying benefit design to
substantially increase cost sharing
(eg, reference pricing) to drive
patients from low-value to highvalue providers.
•C
 reating programs that overlay
benefits (eg, domestic travel
benefits that enable patients to
travel to a destination center for
evaluation and treatment – at no
charge to the employee – thereby
reducing their variation in spend
and outcomes).

Providers may desire to play “moneyball”
for population health, but success
requires a distinct business model
and different competencies than feefor-service care (Figure 2). The small
number of providers with “risk” contracts
have built systems to win in this model.
Most providers are exploring ways to
coordinate fee-for-service populations
through innovative efforts that reap
rewards for total value. Examples
of these programs include bundled
payments, comanagement agreements,
patient-centered medical homes, and
accountable care organizations
(ACOs) (Figure 3). Although ACOs
often are viewed as monolithic, there
are factors that differentiate them –
from the populations they serve
(eg, Medicare, Medicaid, specific
employers, commercially insured) to
program operations (eg, attribution
to benchmarks, provider networks).
Although some ACOs assume
financial risk (and have been doing so
for many years before they were called
ACOs), most are contracting fee-forservice with a shared savings based on
reduction in total expenses (upsideonly shared savings).
There are various models, but the
bottom line is that the most profitable
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option for high-volume providers is the
least desirable – ie, the current one with
unnecessary care. The math on shared
savings will yield less aggregate revenue
than the status quo.
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Figure 3. Care Delivery Transformation

Half of the nation’s ACOs do not
include a hospital partner – these
organizations stand to benefit from
a reduction in acute care volume
without a reduction in their revenue.
In addition, the technological and
operational infrastructure required to
fully implement the population health
model is fundamentally different from
volume health care.
Providers must consider how to operate
their core businesses as efficiently as
possible while determining whether
to make the substantial investments
necessary to create a population health
management business. The popular
strategy of becoming a population
health manager at the expense of your
core business is a certain road to failure.
Although there will be pressure on the
acute care system, there is and will be
value associated with better care. There
is no bridge from volume to value as
they are separate business models.
The allure of population health
also can lead to a desire to assemble
components under a single umbrella
organization. This is practical in the
absence of willing partners in a market,
but what happens when your hospital
is more expensive and doesn’t deliver
as high quality? Do you compromise
the performance of the ACO at the
expense of the system to keep the
volume “in the family”?
Having patients in high-deductible
health plans plays an important

Source: Centers for Medicare & Medicaid Services. Updates from CMS: value-based purchasing, ACOs and other initiatives, March 19,
2012. http://www.ehcca.com/presentations/pfpsummit7/thompson_1.pdf . Accessed November 25, 2013. ACO, accountable care organization;
PCORI, Patient-Centered Outcomes Research Institute; REC, Regional Extension Center

supportive role in the success of provider
value models. Although seemingly
unrelated, patient engagement and
malpractice liability are being addressed
as patients with “money on the line”
take more active roles in making
decisions. Often, patients with highdeductible plans become engaged and
seek appropriate rather than maximum
utilization. This helps providers to make
sound recommendations without fear of
litigation for avoiding a test or procedure.
Conclusion
Most health care is local, and each market
will evolve differently depending on supply
and demand as well as the insurance
market. There is a big opportunity today
to play “moneyball.” Markets are moving
rapidly as patients enroll in new insurance

products and employers change benefits
or create new programs. Providers can
enter into shared savings arrangements
and focus on care management and
patient engagement and be rewarded for
their results. Be ready to play the game
differently if you want to win.
Brian Silverstein, MD, is President of
HC Wisdom. He can be reached at:
brian@silverstein.biz.
Thanks to Emme Deland, MBA, Kevin
Shah, MD, MBA and Jen Baker, MSHA for
their editorial assistance.
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Redefining Care Management to Address Increasing Fragmentation in Health Care
By Michael Kobernick, MD, MS
A patient presents at a physician’s office
with chest pain. On the basis of a chest
X-ray, the physician believes the patient
has a pneumothorax (collapsed lung) and
calls the emergency department (ED) to
notify the triage nurse that the patient is
coming. The physician does not send the
X-ray with the patient so, after assessment
in the ED, the patient is taken for a
second X-ray to confirm the diagnosis.
While in the radiology department, the
patient’s heart stops. Assuming that the
referring physician’s diagnosis is correct,
the emergency physician places a chest
tube into the patient’s lung. When the
patient’s condition does not improve,
an electrocardiogram is performed
revealing a myocardial infarction. The
patient is referred to a cardiologist for
an intervention but, because a history
of allergies was not elicited in the ED,
the patient has an allergic reaction
to the contrast dye necessitating the
administration of steroids. The steroids
cause a stomach ulcer to hemorrhage.
Eventually the patient goes home with
many physical limitations and is unable
to return to work.
Although the foregoing scenario is
hypothetical, this pattern of expensive
care and poor outcomes – the result
of care delivery fragmentation – is
prevalent in the US health care system.
Shih and colleagues summarize the
issue well in their article for the
Commonwealth Fund1:
“The fragmentation of our delivery system
is a fundamental contributor to the overall
performance of the US health care system.
•P
 atients and families navigate
unassisted across different providers and

care settings, fostering frustrating and
dangerous patient experiences;
•P
 oor communication and lack of clear
accountability for a patient among
multiple providers lead to medical errors,
waste, and duplication;
•T
 he absence of peer accountability,
quality improvement infrastructure, and
clinical information systems foster poor
overall quality of care; and
•H
 igh-cost, intensive medical intervention
is rewarded over higher-value primary
care, including preventive medicine and
the management of chronic illness.”
The result is that “the United States
spends more than any other country
on health care but still ranks in the
bottom half of industrial countries
in outcomes like life expectancy and
infant mortality.”2 Enthoven defines
fragmentation as “the systematic
misalignment of incentives, or lack of
coordination, that spawns inefficient
allocation of resources or harm to
patients. Fragmentation adversely
impacts quality, cost, and outcomes.”3
A variety of health care services have
been developed in the areas of wellness,
disease management, and complex case
management to address specific medical
needs and reduce fragmentation.
Wellness programs classify individuals
into risk groups and apply educational
interventions designed to help them
stay “healthier,” be more engaged in
their own health, and incur reduced
costs. Disease management focuses on
groups of individuals with a particular
diagnosis and provides broad programs
targeted to the condition. Complex case

management addresses the individual
needs of the sickest individuals.
Because each of these programs has
been developed in isolation from
the others, they inadvertently have
contributed to the fragmentation of
health care described.
With this in mind, a new definition
of care management (CM) is apropos.
CM is the integration of traditional
wellness, disease management (also
known as “care gap closure”), complex
care management, and care transition
programs into a series of patientcentered interventions that use
elements from each as appropriate.
CM recognizes that services are
simultaneously “horizontal” and
“vertical.” “Horizontal” refers to the
natural progression of disease along
a continuous time line, generally
from healthy to sick. At any given
point along the continuum, there are
associated interventions from any or all
of the care management groups. Many
interventions are “vertical,” reflecting
the severity of disease, from low-risk
primary care to complex specialty care.
In a practical sense, the CM
coordinators who interact with patients
must be educated in the natural history
of the disease and the interventions
traditionally applied to each group.
At any given time a patient may need
guidance in all of the groups. For
instance, a patient with congestive heart
failure may require:
• Wellness advice about a pap test and
immunizations.
• Disease management services for
hypertension and obesity.
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• Complex case management
services to help with medication
reconciliation, daily weights, and
regular physician appointments to
avoid admissions.
Integrating the education and services
provided by a CM coordinator is the
best way to improve outcomes and
reduce costs.
The effectiveness of the CM
coordinator is dependent on the ability
of our health care system to aggregate
patient information in electronic
health records and to make this
information available to all providers
at any time. In the example presented,
such information sharing could have
prevented many of the errors. The
chest X-ray would have been available
to the emergency physician, who would
have noticed an artifact masquerading
as air in the chest. A detailed history
of allergies would have avoided the
allergic reaction.
In addition to personal health
data, aggregate information from

populations must be collected in a
format that allows for group analysis,
the generation of targeted population
interventions, and the ability to
measure the success of such programs.
Data collection and reporting are
essential elements in curing the
problem of fragmentation in delivering
care to individuals in the population.
Poor communication with the
individual and family is another
source of fragmentation. Who among
us has not experienced confusion
and concern when told we need
certain serious health care services?
People frightened by the lack of
empathetic communication often seek
reassurance in settings that add to the
fragmentation of care. Integration
of CM includes attention to the
relationship of the care team with
the individual patient and his or her
family. Beyond clinical protocols, CM
coordinators need help in acquiring
the skills necessary for developing
a trusting relationship with the
patient. The essence of any healing
relationship hinges on the balance
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between the clinical science and
personal interaction.
The next iteration of health care
reforms must seek to cure the
fragmentation that exists in our
current system. This requires that
we understand the natural history
of disease, matching interventions
to the course of the illness with
compassionate understanding.
Michael Kobernick, MD, MS, is Chief
Medical Officer at Ascension Health SmartHealth. He can be reached at:
michael.kobernick@ascensionhealth.org.
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